EN | RU
EN | RU

Help Support

Back

Impact of anti-CD20 therapy on humoral responses to SARS-CoV-2 vaccines in multiple sclerosis

multiple_sclerosis multiple_sclerosis
multiple_sclerosis multiple_sclerosis

This retrospective observational study was held to examine the duration of the anti-CD20 therapy-induced impact on humoral responses to SARS-CoV-2 vaccines.

See All

Key take away

In people with multiple sclerosis, anti-CD20 elicited suppression of humoral responses to COVID-19 vaccines is temporary. Production of antibodies was more prominent >18 months following termination of anti-CD20 therapy.

Background

This retrospective observational study was held to examine the duration of the anti-CD20 therapy-induced impact on humoral responses to SARS-CoV-2 vaccines.

Method

Multiple sclerosis patients who had discontinued anti-CD20 treatment for ⩾12 months and were devoid of immunomodulation were incorporated. Retrieval was done of demographics and lab parameters including B-cell counts and immunoglobulin (IgA, IgM, IgG) levels before anti-CD20 initiation (baseline) and longitudinally after anti-CD20 therapy cessation from the electronic medical records. A comparison was done between humoral responses to coronavirus vaccines and a population of 11 multiple sclerosis people with ongoing anti-CD20 medication (control cohort).

Result

Overall, 24 multiple sclerosis patients discontinued anti-CD20 treatment for an average of 34 months. Antibody responses to coronavirus vaccines were available in 71% (17 people). Majority of people induced a quantifiable response of antibody to COVID-19 immunization on average 22 months from the last anti-CD20 infusion, which was higher in comparison with the population with ongoing anti-CD20 treatment.

Compared with the control cohort, remarkably elevated antibody levels were found among multiple sclerosis patients (vaccinated >18 months post-treatment discontinuation). Notably, 18 months post discontinuation of the therapy, mean B-cell counts approached normal ranges and the interindividual kinetics for the B-cell reconstitution were found to be heterogeneous. The humoral responses to the coronavirus vaccine were not correlated to B-cell recovery as no correlation between vaccine responses and B-cell repopulation was seen. Mean total IgA, IgM, and IgG levels continued to be in the reference range.

Conclusion

The immunological ‘scar’ of anti-CD20 therapy concerning vaccine responses and B-cell counts in multiple sclerosis patients seems to wane 18 months post-anti-CD20 cessation.

Source:

Therapeutic Advances in Neurological Disorders

Article:

Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study

Authors:

Tobias Moser et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: